142 related articles for article (PubMed ID: 20472416)
21. Low knowledge and perceived Hepatitis C risk despite high risk behaviour among injection drug users in Kathmandu, Nepal.
Loewinger G; Sharma B; Karki DK; Khatiwoda P; Kainee S; Poudel KC
Int J Drug Policy; 2016 Jul; 33():75-82. PubMed ID: 27318773
[TBL] [Abstract][Full Text] [Related]
22. Hepatitis C incidence--a comparison between injection and noninjection drug users in New York City.
Fuller CM; Ompad DC; Galea S; Wu Y; Koblin B; Vlahov D
J Urban Health; 2004 Mar; 81(1):20-4. PubMed ID: 15047780
[TBL] [Abstract][Full Text] [Related]
23. Hepatitis C treatment uptake and adherence among injecting drug users in the Czech Republic.
Mravčík V; Strada L; Reimer J; Schulte B
Epidemiol Mikrobiol Imunol; 2014 Nov; 63(4):265-9. PubMed ID: 25523218
[TBL] [Abstract][Full Text] [Related]
24. Hepatitis C virus antibody prevalence among injecting drug users in Glasgow has fallen but remains high.
Goldberg D; Cameron S; McMenamin J
Commun Dis Public Health; 1998 Jun; 1(2):95-7. PubMed ID: 9644121
[TBL] [Abstract][Full Text] [Related]
25. Hepatitis C virus infection in the Middle East and North Africa "MENA" region: injecting drug users (IDUs) is an under-investigated population.
Ramia S; Melhem NM; Kreidieh K
Infection; 2012 Feb; 40(1):1-10. PubMed ID: 22237470
[TBL] [Abstract][Full Text] [Related]
26. Projecting severe sequelae of injection-related hepatitis C virus epidemic in the UK. Part 1: Critical hepatitis C and injector data.
Bird SM; Goldberg DJ; Hutchinson SJ
J Epidemiol Biostat; 2001; 6(3):243-65; discussion 279-85. PubMed ID: 11437088
[TBL] [Abstract][Full Text] [Related]
27. Seroprevalence of anti-hepatitis C virus (anti-HCV) antibody and HCV-related risk in injecting drug users in northern India: comparison with non-injecting drug users.
Basu D; Kumar V; Sharma AK; Barnwal PK; Mattoo SK
Asian J Psychiatr; 2013 Feb; 6(1):52-5. PubMed ID: 23380318
[TBL] [Abstract][Full Text] [Related]
28. High incidence of hepatitis C virus reinfection in a cohort of injecting drug users.
Aitken CK; Lewis J; Tracy SL; Spelman T; Bowden DS; Bharadwaj M; Drummer H; Hellard M
Hepatology; 2008 Dec; 48(6):1746-52. PubMed ID: 18844233
[TBL] [Abstract][Full Text] [Related]
29. Prevalence of HIV, hepatitis B and hepatitis C and associated risk behaviours amongst injecting drug users in three Afghan cities.
Nasir A; Todd CS; Stanekzai MR; Bautista CT; Botros BA; Scott PT; Strathdee SA; Tjaden J
Int J Drug Policy; 2011 Mar; 22(2):145-52. PubMed ID: 21146392
[TBL] [Abstract][Full Text] [Related]
30. Hepatitis C virus infection, HIV co-infection, and associated risk among injecting drug users in Togliatti, Russia.
Rhodes T; Platt L; Judd A; Mikhailova LA; Sarang A; Wallis N; Alpatova T; Hickman M; Parry JV
Int J STD AIDS; 2005 Nov; 16(11):749-54. PubMed ID: 16303071
[TBL] [Abstract][Full Text] [Related]
31. Global epidemiology of hepatitis B and hepatitis C in people who inject drugs: results of systematic reviews.
Nelson PK; Mathers BM; Cowie B; Hagan H; Des Jarlais D; Horyniak D; Degenhardt L
Lancet; 2011 Aug; 378(9791):571-83. PubMed ID: 21802134
[TBL] [Abstract][Full Text] [Related]
32. Liver fibrosis progression at autopsy in injecting drug users infected by hepatitis C: a longitudinal long-term cohort study.
Kielland KB; Delaveris GJ; Rogde S; Eide TJ; Amundsen EJ; Dalgard O
J Hepatol; 2014 Feb; 60(2):260-6. PubMed ID: 24096048
[TBL] [Abstract][Full Text] [Related]
33. Estimating the variability in the risk of infection for hepatitis C in the Glasgow injecting drug user population.
Sutton AJ; McDonald SA; Palmateer N; Taylor A; Hutchinson SJ
Epidemiol Infect; 2012 Dec; 140(12):2190-8. PubMed ID: 22459739
[TBL] [Abstract][Full Text] [Related]
34. The cost-effectiveness of testing for hepatitis C in former injecting drug users.
Castelnuovo E; Thompson-Coon J; Pitt M; Cramp M; Siebert U; Price A; Stein K
Health Technol Assess; 2006 Sep; 10(32):iii-iv, ix-xii, 1-93. PubMed ID: 16948891
[TBL] [Abstract][Full Text] [Related]
35. HCV infection prevalence lower than expected among 18-40-year-old injection drug users in San Diego, CA.
Garfein RS; Rondinelli A; Barnes RF; Cuevas J; Metzner M; Velasquez M; Rodriguez D; Reilly M; Xing J; Teshale EH
J Urban Health; 2013 Jun; 90(3):516-28. PubMed ID: 22766605
[TBL] [Abstract][Full Text] [Related]
36. Injecting risk behaviours following treatment for hepatitis C virus infection among people who inject drugs: The Australian Trial in Acute Hepatitis C.
Alavi M; Spelman T; Matthews GV; Haber PS; Day C; van Beek I; Walsh N; Yeung B; Bruneau J; Petoumenos K; Dolan K; Kaldor JM; Dore GJ; Hellard M; Grebely J;
Int J Drug Policy; 2015 Oct; 26(10):976-83. PubMed ID: 26115881
[TBL] [Abstract][Full Text] [Related]
37. Epidemiology, clinical data, and treatment of viral hepatitis in a large cohort of intravenous drug users.
Gigi E; Sinakos E; Sykja A; Androulakis G; Tanis C; Stayridou V; Tsirogianni E; Zouridakis K; Bellou AL; Orfanou E; Raptopoulou-Gigi M
J Addict Med; 2013; 7(1):52-7. PubMed ID: 23340710
[TBL] [Abstract][Full Text] [Related]
38. Alarming epidemics of human immunodeficiency virus and hepatitis C virus among injection drug users in the northwestern bordering state of Punjab, India: prevalence and correlates.
Panda S; Roy T; Pahari S; Mehraa J; Sharma N; Singh G; Singh J; Joseph F; Singh S; Sharma NM
Int J STD AIDS; 2014 Jul; 25(8):596-606. PubMed ID: 24352120
[TBL] [Abstract][Full Text] [Related]
39. HIV, Hepatitis C, and Abstinence from Alcohol Among Injection and Non-injection Drug Users.
Elliott JC; Hasin DS; Stohl M; Des Jarlais DC
AIDS Behav; 2016 Mar; 20(3):548-54. PubMed ID: 26080690
[TBL] [Abstract][Full Text] [Related]
40. Risk behaviors, prevalence of HIV and hepatitis C virus infection and population size of current injection drug users in a China-Myanmar border city: results from a Respondent-Driven Sampling Survey in 2012.
Li L; Assanangkornchai S; Duo L; McNeil E; Li J
PLoS One; 2014; 9(9):e106899. PubMed ID: 25203256
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
